Akneymcin plus

• Photosensitivity may occur during treatment with Aknemycin Plus. Exposure to sunlight should be minimised and the use of sun lamps or sunbeds avoided during treatment. Patients with sunburn should not use this product until recovered because of the increased susceptibility to sunlight whilst using tretinoin. Wind and rain may be unusually irritating to patients under treatment.
• Accumulation of the product in skin folds or in the angles of the nose should be avoided.
• The product should not be allowed to come into contact with the eyes or eyelids - if this occurs, thorough rinsing with water is recommended.
• As with other macrolides, rare serious allergic reactions, including acute generalised exanthematous pustulosis (AGEP) have been reported. If an allergic reaction occurs, the drug should be discontinued and appropriate therapy should be instituted. Physicians should be aware that reappearance of the allergic symptoms may occur when symptomatic therapy is discontinued.
• This medicine contains 752 mg of alcohol (ethanol) in each ml. It may cause burning sensation on damaged skin.
• Do not light a cigarette or expose yourself to flame until the medicine has dried completely.

Use as instructed by your doctor or pharmacist.

Aknemycin Plus 4.0% w/w and 0.025% w/w cutaneous solution

There may be rare cases of skin irritation in the form of erythema, burning, drying or peeling of the skin may be observed. In very rare cases the above symptoms may also be an expression of a hypersensitivity reaction (allergic contact eczema). There may be an apparent deterioration in acne with an increase in inflammatory symptoms at the commencement of treatment; this is a sign that the medicine is beginning to act and is usually transitory. If the above occurs, treatment should not be interrupted but the frequency of application is reduced. Rarely, temporary hypopigmentation or hyperpigmentation has been reported in individuals treated with tretinoin. Temporary depigmentation in non-Caucasians is possible.